How to Get Evenity (Romosozumab) in Nebraska

What Romosozumab Is and Why Access Matters

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation and decreases bone resorption, a dual mechanism unique among osteoporosis therapies 1. The FDA approved Evenity in April 2019 for postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture, or patients who have failed other therapies 2.

Nebraska has roughly 145,000 women over age 65 with osteoporosis based on national prevalence data from the CDC 3. Access in the state depends on prescriber availability, insurance type, and pharmacy logistics. Understanding each step of the process prevents delays that leave high-risk patients exposed to fracture.

Step 1: Find a Qualified Prescriber in Nebraska

Any physician (MD or DO), nurse practitioner, or physician assistant licensed in Nebraska can prescribe Evenity. NPs in Nebraska practice under a transitional-to-practice agreement for the first 2 to 000 hours, after which they gain full practice authority, including the ability to prescribe specialty biologics independently 4. PAs prescribe under a collaborative agreement with a supervising physician.

For patients in rural counties, telehealth expands options significantly. Nebraska law permits telehealth prescribing by any provider holding a valid Nebraska license. A 2023 Endocrine Society clinical practice guideline recommends that patients with osteoporosis and prior fracture be evaluated for anabolic therapy (including romosozumab) before starting antiresorptive treatment alone 5. If your local primary care provider is unfamiliar with romosozumab, a telehealth consultation with an endocrinologist or rheumatologist is a practical alternative.

Step 2: Baseline Labs and Clinical Workup

Before prescribing romosozumab, your provider will order a set of baseline labs. These are not optional; they determine eligibility and safety.

Required labs typically include:

• Serum calcium (corrected for albumin) to rule out hypocalcemia, which must be corrected before treatment 6
• 25-hydroxyvitamin D level, with repletion to at least 30 ng/mL recommended before initiating therapy
• Basic metabolic panel including creatinine and eGFR
• DXA scan with T-scores at the lumbar spine, femoral neck, and total hip
• FRAX score calculation, especially if the T-score falls between -1.0 and -2.5 with risk factors

A DXA T-score of -2.5 or below at any measured site confirms an osteoporosis diagnosis per WHO criteria 7. The AACE/ACE 2020 guidelines classify patients as "very high risk" when they have a T-score of -3.0 or below, a recent vertebral fracture, or fractures while on approved osteoporosis therapy. These are the patients most likely to benefit from romosozumab as first-line anabolic treatment 8.

Your provider should also assess cardiovascular risk. The Evenity label carries a boxed warning about potential increased risk of myocardial infarction, stroke, and cardiovascular death 2. Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding 12 months.

Step 3: Manage Prior Authorization in Nebraska

Almost every insurer requires prior authorization for Evenity. The process varies by payer but follows a general pattern.

Documentation your provider will need to submit:

• DXA results confirming osteoporosis (T-score ≤ -2.5) or severe osteopenia with fragility fracture
• FRAX score or clinical documentation of high fracture risk
• Record of prior antiresorptive therapy failure or intolerance (many insurers require this)
• Cardiovascular risk assessment confirming no recent MI or stroke
• Lab results showing corrected calcium and vitamin D levels

Commercial plans in Nebraska typically process prior authorizations within 5 to 15 business days. Medicare Part B covers Evenity as a physician-administered drug under the medical benefit rather than the pharmacy benefit, which means the injection is billed through the provider's office and requires a different prior authorization pathway 9.

Nebraska Medicaid does not cover Evenity. Patients on Medicaid may need to explore manufacturer assistance programs. Amgen offers the Evenity Co-pay Card for commercially insured patients, reducing out-of-pocket costs to as little as $5 per injection. For uninsured patients, the Amgen Safety Net Foundation provides Evenity at no cost to qualifying individuals 10.

The Clinical Evidence Behind Romosozumab

The FRAME trial (N=7,180) compared romosozumab 210 mg monthly to placebo for 12 months, followed by denosumab in both groups. At 12 months, romosozumab reduced new vertebral fractures by 73% compared to placebo (0.5% vs. 1.8%, P<0.001) 11. The benefit persisted through 24 months after transition to denosumab.

The ARCH trial (N=4,093) tested romosozumab against alendronate, both followed by alendronate. At 24 months, romosozumab-to-alendronate reduced new vertebral fractures by 48% compared to alendronate alone (6.2% vs. 11.9%, P<0.001) 6. Hip fracture risk dropped by 38%. The trial also identified a cardiovascular safety signal: adjudicated major adverse cardiac events occurred in 2.5% of the romosozumab group versus 1.9% in the alendronate group during the first 12 months.

A 2020 meta-analysis published in the Journal of Bone and Mineral Research pooled data from both trials and found that the absolute cardiovascular risk difference was small but statistically detectable in the ARCH population, which had higher baseline cardiovascular risk than FRAME participants 12. The Endocrine Society recommends shared decision-making about cardiovascular risk before initiating romosozumab 5.

Bone mineral density gains with romosozumab are the largest reported for any osteoporosis therapy. At the lumbar spine, 12 months of treatment produced a mean 13.3% increase from baseline in BMD, compared to 5.0% for teriparatide (Forteo) over the same period in a head-to-head trial 13.

Step 4: Pharmacy and Administration Logistics

Evenity is administered as two subcutaneous injections (each 105 mg/1.17 mL) given in the abdomen, thigh, or upper arm during a single visit. The full 210 mg dose is split across two prefilled syringes. Each injection goes to a different site.

The drug is not available at retail pharmacies. It is a buy-and-bill product: the prescriber's office orders it from a specialty distributor, stores it under refrigeration (2°C to 8°C), and administers it on-site. Some patients receive injections at infusion centers.

Nebraska has specialty pharmacies that can ship Evenity directly to provider offices. Common distributors include McKesson, AmerisourceBergen, and Cardinal Health. Delivery typically takes 3 to 7 business days after prior authorization approval 14.

Regarding 503A compounding pharmacies: while Nebraska does license 503A compounding facilities, romosozumab is a biologic (a monoclonal antibody) and cannot be legally compounded. Biologics require FDA-approved manufacturing facilities. Any pharmacy claiming to compound romosozumab would be operating outside federal law 15.

The 12-Month Treatment Window and What Comes After

Romosozumab is approved for a maximum of 12 monthly doses. This is not flexible. The anabolic window of sclerostin inhibition shows diminishing returns beyond 12 months as anti-drug antibodies may develop and the modeling-based bone formation effect plateaus 6.

After completing 12 doses, transition to an antiresorptive agent is required to maintain the bone density gained. Without follow-up therapy, BMD declines rapidly within 12 months, similar to the rebound seen after discontinuing denosumab 16.

The two standard transition options are:

Denosumab (Prolia): 60 mg subcutaneous injection every 6 months. The FRAME extension data showed that patients who transitioned from romosozumab to denosumab maintained and continued to gain BMD through 36 months 11.

Alendronate (Fosamax): 70 mg oral tablet weekly. Less BMD preservation than denosumab, but avoids the rebound fracture risk associated with denosumab discontinuation. The ARCH trial used this sequence and still demonstrated significant fracture reduction 6.

Your provider should plan the transition before you begin romosozumab. Missing even one month between romosozumab completion and antiresorptive initiation risks losing the BMD gained.

Cost Breakdown and Financial Assistance

Evenity carries a wholesale acquisition cost of approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-dose course. Actual out-of-pocket costs depend entirely on insurance.

Medicare Part B: Covers 80% of the allowed amount after the annual deductible. Patients typically pay 20% coinsurance unless they carry a Medigap supplemental plan. For a $1,825 dose, the monthly out-of-pocket would be roughly $365 before any supplemental coverage.

Commercial insurance: Most plans cover Evenity after prior authorization. Amgen's co-pay card reduces patient responsibility to $5 per dose for eligible commercially insured patients.

Nebraska Medicaid: Not covered. Patients may apply to the Amgen Safety Net Foundation for free drug access 10.

Uninsured patients: The Safety Net Foundation income threshold is typically 300% of the federal poverty level. An uninsured 68-year-old in Lincoln earning $40,000 annually would likely qualify.

The American Association of Clinical Endocrinology recommends that cost should not be the sole reason to withhold anabolic therapy from very-high-risk patients, given the downstream cost of hip fractures (averaging $44,600 per hospitalization) 8.

Timeline: From First Appointment to First Injection

A realistic Nebraska-specific timeline looks like this:

• Week 1: Initial consultation (in-person or telehealth), lab orders placed
• Week 2: DXA scan and blood work completed
• Week 3: Provider reviews results, submits prior authorization
• Weeks 3 to 5: Prior authorization processing (5 to 15 business days for commercial plans; Medicare may take longer)
• Week 5 to 6: Drug ordered, shipped to provider office
• Week 6 to 7: First injection administered

Total time from initial appointment to first dose: approximately 6 to 7 weeks in a straightforward case. Prior authorization denials add 2 to 4 weeks for peer-to-peer review and appeals. Patients with recent fractures should have their provider request an expedited or urgent prior authorization, which most Nebraska insurers must process within 72 hours 17.

Cardiovascular Screening Before Starting

The boxed warning on Evenity's label requires attention, not avoidance. A 2021 analysis published in the Journal of the American Heart Association examined cardiovascular outcomes across all romosozumab trials and found that the absolute risk increase was confined largely to patients with pre-existing atherosclerotic cardiovascular disease 18. Patients without established cardiovascular disease showed no statistically significant increase in cardiac events.

Before prescribing, your provider should assess 10-year ASCVD risk using the ACC/AHA pooled cohort equations. Patients with a calculated risk above 20% or a history of MI, stroke, or TIA within the prior year should not receive romosozumab. For patients with moderate cardiovascular risk (10 to 20%), a shared decision-making conversation weighing fracture risk against cardiovascular risk is appropriate 5.

An EKG is not required by the label but is reasonable in patients over 70 with hypertension or diabetes. Baseline lipid panels help document cardiovascular risk status before treatment.